Lantheus Holdings: Tensions From The PDUFA Extension

BiologicsInvesting Group LeaderFollow5ShareSavePlay(12min)CommentsSummaryLantheus Holdings faces a three-month FDA PDUFA extension for OCTEVY, delaying potential approval and launch to June 2026.OCTEVY’s extension is procedural, tied to manufacturing review, not efficacy or safety, and is not expected to impact its clinical adoption pathway.While OCTEVY alone won’t restore double-digit growth, it can stabilize near-term revenue and support LNTH’s strategic pivot to PET radiodiagnostics.I maintain a 3 out of 5 conviction rating on LNTH, monitoring technical signals and FDA developments before considering additional position sizing.Looking for a helping hand in the market? Members of Compounding Healthcare get exclusive ideas and guidance to navigate any climate. Learn More » Richard Drury/DigitalVision via Getty Images It has been over two years since my last Lantheus Holdings, Inc. (LNTH) article, where I reviewed the market's reaction to Point Biopharma and Lantheus Holdings releasing positive topline results for their radioligand therapy in patients with metastaticThis article was written byBiologics9.74K FollowersFollowBiologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions. He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of LNTH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.